Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BRADLEY M BLOCK

Allopathic & Osteopathic Physicians Family Medicine

NPI
1205819307
CMS profile
191172
Location
OVIEDO, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$376.65

20 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $376.65 20

By paying entity

PY2024 · entire year · sorted by reported total

Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BRADLEY M BLOCK

NPI 1205819307 · CMS profile ID 191172

Allopathic & Osteopathic Physicians / Family Medicine

OVIEDO, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1205819307?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BRADLEY M BLOCK, NPI 1205819307, CMS profile ID 191172. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1205819307?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). BRADLEY M BLOCK, NPI 1205819307, CMS profile ID 191172. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1205819307?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
BRADLEY M BLOCK, NPI 1205819307, CMS profile ID 191172, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1205819307?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

20 matching records · $376.65 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 20 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–20 of 20.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
IDORSIA PHARMACEUTICALS US INC $14.7411/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146792698 CMS
Renalytix AI, Inc. $20.1309/11/2024 Food and Beverage No dispute reported Delay: No
Change: CHANGED
06/30/2026 1116758542 CMS
Renalytix AI, Inc. $18.1508/28/2024 Food and Beverage No dispute reported Delay: No
Change: CHANGED
06/30/2026 1116758540 CMS
Esperion Therapeutics, Inc. $19.0008/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1129428538 CMS
SANOFI-AVENTIS U.S. LLC $27.4007/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139591392 CMS
ABBVIE INC. $28.6907/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103337644 CMS
ABBVIE INC. $18.8307/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103337642 CMS
ABBVIE INC. $24.3706/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103337640 CMS
ABBVIE INC. $12.2205/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103337638 CMS
ABBVIE INC. $8.2305/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103337636 CMS
ABBVIE INC. $13.6705/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103337634 CMS
Abbott Laboratories $21.2505/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1124899883 CMS
ABBVIE INC. $8.2004/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103337632 CMS
ABBVIE INC. $20.1204/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103337630 CMS
ABBVIE INC. $6.9804/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103337628 CMS
Axsome Therapeutics, Inc. $28.4802/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148268250 CMS
AstraZeneca Pharmaceuticals LP $16.8702/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105565084 CMS
Exact Sciences Corporation $21.4402/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114594325 CMS
Lilly USA, LLC $19.0902/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136074757 CMS
PhotoniCare Inc $28.7901/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1081237696 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $205.15 15
PY2020 $3,246.75 19
PY2021 $143.76 10
PY2022 $189.20 11
PY2023 $1,359.11 9
PY2024 $376.65 20
PY2025 $4,527.48 9

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $463,347.97 19
PY2024 Recipient $32,803.00 1
PY2024 Principal investigator $565,590.10 69
PY2023 Recipient $285.00 1
PY2023 Principal investigator $529,627.42 655
PY2022 Recipient $610.00 1
PY2022 Principal investigator $122,619.06 206
PY2021 Recipient $396.44 1
PY2021 Principal investigator $386,856.51 126
PY2020 Recipient $2,077.00 3
PY2020 Principal investigator $684,365.10 151
PY2019 Recipient $1,843.74 2
PY2019 Principal investigator $278,906.72 78

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

80 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Novo Nordisk AS $1,283.63 12/23/2019 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH LLC
EX9536-4388 No dispute reported 06/30/2026 692457729
Recipient Eli Lilly and Company $307.13 12/19/2019 Covered Recipient Physician EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT- RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-1) No dispute reported 06/30/2026 654281105
Principal investigator 1 Novo Nordisk AS $24.99 12/16/2019 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706701217
Principal investigator 1 Novo Nordisk AS $15,426.60 12/03/2019 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH LLC
NN2211-4232 No dispute reported 06/30/2026 692457699
Principal investigator 1 Novo Nordisk AS $1,000.00 12/03/2019 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH LLC
NN2211-4232 No dispute reported 06/30/2026 692457701
Principal investigator 1 Novo Nordisk AS $2,130.20 12/03/2019 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH LLC
EX9536-4388 No dispute reported 06/30/2026 692457727
Principal investigator 1 Novo Nordisk AS $24.99 11/27/2019 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706701215
Principal investigator 1 PFIZER INC. $41,440.50 11/27/2019 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND ACTIVECONTROLLED MULTICENTER STUDY OF THE LONGTERM SAFETY AND EFFICACY OF SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR KNEE No dispute reported 06/30/2026 671658965
Principal investigator 1 Novo Nordisk AS $24.99 11/21/2019 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706701213
Principal investigator 1 Eli Lilly and Company $558.00 11/18/2019 Non-covered Recipient Entity
COMPASS RESEARCH EAST LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY2951742 IN PATIENTS WITH CHRONIC MIGRAINE - THE REGAIN STUDY No dispute reported 06/30/2026 654292635
Principal investigator 1 Eli Lilly and Company $2,186.26 11/11/2019 Non-covered Recipient Entity
COMPASS RESEARCH EAST LLC
EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT- RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-1) No dispute reported 06/30/2026 654289149
Principal investigator 1 Eli Lilly and Company $96,934.00 10/29/2019 Non-covered Recipient Entity
COMPASS RESEARCH EAST LLC
A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL COMPARING EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS SEMAGLUTIDE ONCE WEEKLY AS ADD-ON THERAPY TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES No dispute reported 06/30/2026 654291681
Principal investigator 1 Novo Nordisk AS $2,186.45 10/29/2019 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH LLC
EX9536-4388 No dispute reported 06/30/2026 692457719
Principal investigator 1 Novo Nordisk AS $2,197.70 09/26/2019 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH LLC
EX9536-4388 No dispute reported 06/30/2026 692457725
Principal investigator 1 Novo Nordisk AS $3,638.83 08/30/2019 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH LLC
EX9536-4388 No dispute reported 06/30/2026 692457723
Principal investigator 1 Eisai Inc. $558.00 08/22/2019 Non-covered Recipient Entity
COMPASS RESEARCH, LLC
A Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel Group Study of the Safety and Efficacy of Lemborexant in Subjects With Insomnia Disorder No dispute reported 06/30/2026 702524989
Principal investigator 1 Eisai Inc. $3,991.25 08/22/2019 Non-covered Recipient Entity
COMPASS RESEARCH, LLC
A Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel Group Study of the Safety and Efficacy of Lemborexant in Subjects With Insomnia Disorder No dispute reported 06/30/2026 702524991
Principal investigator 1 Novo Nordisk AS $4,143.40 07/30/2019 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH LLC
EX9536-4388 No dispute reported 06/30/2026 692457721
Recipient Eli Lilly and Company $1,536.61 07/19/2019 Covered Recipient Physician A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL COMPARING EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS SEMAGLUTIDE ONCE WEEKLY AS ADD-ON THERAPY TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES No dispute reported 06/30/2026 654281367
Principal investigator 1 AMAG Pharmaceuticals, Inc. $2,650.00 07/12/2019 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH
Prasterone DHEA for the Treatment of Hypoactive Sexual Desire Disorder HSDD - Placebo-Controlled, Double Blind and Randomized Phase III Study of Intravaginal Prasterone No dispute reported 06/30/2026 698958339
Principal investigator 1 Eli Lilly and Company $6,684.48 07/05/2019 Non-covered Recipient Entity
COMPASS RESEARCH EAST LLC
A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL COMPARING EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS SEMAGLUTIDE ONCE WEEKLY AS ADD-ON THERAPY TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES No dispute reported 06/30/2026 654290661
Principal investigator 1 PFIZER INC. $48.00 07/01/2019 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH
A PHASE 3 RANDOMIZED DOUBLEBLIND ACTIVECONTROLLED MULTICENTER STUDY OF THE LONGTERM SAFETY AND EFFICACY OF SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR KNEE No dispute reported 06/30/2026 671638311
Principal investigator 1 Novo Nordisk AS $3,549.95 06/25/2019 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH LLC
EX9536-4388 No dispute reported 06/30/2026 692457717
Principal investigator 1 Novo Nordisk AS $7.90 06/18/2019 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706701209
Principal investigator 1 Novo Nordisk AS $12.98 06/18/2019 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706701211
Principal investigator 1 Novo Nordisk AS $75.00 06/11/2019 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706701207
Principal investigator 1 PFIZER INC. $48.00 06/01/2019 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH
A PHASE 3 RANDOMIZED DOUBLEBLIND ACTIVECONTROLLED MULTICENTER STUDY OF THE LONGTERM SAFETY AND EFFICACY OF SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR KNEE No dispute reported 06/30/2026 671638383
Principal investigator 1 Novo Nordisk AS $7,279.34 05/28/2019 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH LLC
EX9536-4388 No dispute reported 06/30/2026 692457715
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $517.00 05/15/2019 Non-covered Recipient Entity
Oviedo Medical Research
Bay1002670 Fibroids Efficacy US / EU No dispute reported 06/30/2026 629180013
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,275.00 05/13/2019 Non-covered Recipient Entity
Oviedo Medical Research
Bay1002670 Fibroids Efficacy US / EU No dispute reported 06/30/2026 629178863
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $54.00 05/13/2019 Non-covered Recipient Entity
Oviedo Medical Research
Bay1002670 Fibroids Efficacy US / EU No dispute reported 06/30/2026 629179155
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $8,582.00 05/13/2019 Non-covered Recipient Entity
Oviedo Medical Research
Bay1002670 Fibroids Efficacy US / EU No dispute reported 06/30/2026 629179301
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,620.00 05/13/2019 Non-covered Recipient Entity
Oviedo Medical Research
Bay1002670 Fibroids Efficacy US / EU No dispute reported 06/30/2026 629179447
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $110.00 05/13/2019 Non-covered Recipient Entity
Oviedo Medical Research
Bay1002670 Fibroids Efficacy US / EU No dispute reported 06/30/2026 629179881
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $457.00 05/13/2019 Non-covered Recipient Entity
Oviedo Medical Research
Bay1002670 Fibroids Efficacy US / EU No dispute reported 06/30/2026 629180145
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $266.00 05/13/2019 Non-covered Recipient Entity
Oviedo Medical Research
Bay1002670 Fibroids Efficacy US / EU No dispute reported 06/30/2026 629180655
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $54.00 05/13/2019 Non-covered Recipient Entity
Oviedo Medical Research
Bay1002670 Fibroids Efficacy US / EU No dispute reported 06/30/2026 629181023
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $355.00 05/13/2019 Non-covered Recipient Entity
Oviedo Medical Research
Bay1002670 Fibroids Efficacy US / EU No dispute reported 06/30/2026 629181261
Principal investigator 1 Flexion Therapeutics, Inc. $10,135.00 05/01/2019 Non-covered Recipient Entity
COMPASS RESEARCH
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of FX006 in Patients with Hip Osteoarthritis No dispute reported 06/30/2026 705979645
Principal investigator 1 PFIZER INC. $48.00 05/01/2019 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH
A PHASE 3 RANDOMIZED DOUBLEBLIND ACTIVECONTROLLED MULTICENTER STUDY OF THE LONGTERM SAFETY AND EFFICACY OF SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR KNEE No dispute reported 06/30/2026 671638435
Principal investigator 1 Novo Nordisk AS $675.57 04/25/2019 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH LLC
EX9536-4388 No dispute reported 06/30/2026 692457713
Principal investigator 1 SANOFI US SERVICES INC. $3,480.00 04/25/2019 Non-covered Recipient Entity
Oviedo Medical Research LLC
A 26-week Randomized, Double-blind, Controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Empagliflozin, and Placebo in Patients With Type 2 Di No dispute reported 06/30/2026 691556269
Principal investigator 1 SANOFI US SERVICES INC. $1,000.00 04/23/2019 Non-covered Recipient Entity
Oviedo Medical Research LLC
A 26-week Randomized, Double-blind, Controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Empagliflozin, and Placebo in Patients With Type 2 Di No dispute reported 06/30/2026 691555485
Principal investigator 1 Novo Nordisk AS $24.99 04/17/2019 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706701205
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $185.00 04/15/2019 Non-covered Recipient Entity
OVIEDO MEDCL RESEARCH, LLC
COPD pragmatic randomised clinical trial No dispute reported 06/30/2026 704143303
Principal investigator 1 Novo Nordisk AS $24.99 04/03/2019 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706701203
Principal investigator 1 PFIZER INC. $48.00 04/01/2019 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH
A PHASE 3 RANDOMIZED DOUBLEBLIND ACTIVECONTROLLED MULTICENTER STUDY OF THE LONGTERM SAFETY AND EFFICACY OF SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR KNEE No dispute reported 06/30/2026 671638437
Principal investigator 1 Novo Nordisk AS $2,333.26 03/26/2019 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH LLC
EX9536-4388 No dispute reported 06/30/2026 692457711
Principal investigator 1 Novo Nordisk AS $24.99 03/11/2019 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706701201
Principal investigator 1 PFIZER INC. $48.00 03/01/2019 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH
A PHASE 3 RANDOMIZED DOUBLEBLIND ACTIVECONTROLLED MULTICENTER STUDY OF THE LONGTERM SAFETY AND EFFICACY OF SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR KNEE No dispute reported 06/30/2026 671638385
Principal investigator 1 SANOFI US SERVICES INC. $3,800.00 02/25/2019 Non-covered Recipient Entity
Oviedo Medical Research LLC
A 26-week Randomized, Double-blind, Controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Empagliflozin, and Placebo in Patients With Type 2 Di No dispute reported 06/30/2026 691545975
Principal investigator 1 SANOFI US SERVICES INC. $1,127.00 02/25/2019 Non-covered Recipient Entity
Oviedo Medical Research LLC
A 26-week Randomized, Double-blind, Controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Empagliflozin, and Placebo in Patients With Type 2 Di No dispute reported 06/30/2026 691545981
Principal investigator 1 Novo Nordisk AS $26.00 02/12/2019 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706701199
Principal investigator 1 Novo Nordisk AS $1.70 02/08/2019 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706701197
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $982.00 02/07/2019 Non-covered Recipient Entity
Oviedo Medical Research
Bay1002670 Fibroids Efficacy US / EU No dispute reported 06/30/2026 629181143
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,708.00 02/06/2019 Non-covered Recipient Entity
Oviedo Medical Research
Bay1002670 Fibroids Efficacy US / EU No dispute reported 06/30/2026 629178711
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,537.00 02/06/2019 Non-covered Recipient Entity
Oviedo Medical Research
Bay1002670 Fibroids Efficacy US / EU No dispute reported 06/30/2026 629179009
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,708.00 02/06/2019 Non-covered Recipient Entity
Oviedo Medical Research
Bay1002670 Fibroids Efficacy US / EU No dispute reported 06/30/2026 629179593
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $868.00 02/06/2019 Non-covered Recipient Entity
Oviedo Medical Research
Bay1002670 Fibroids Efficacy US / EU No dispute reported 06/30/2026 629179737
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $958.00 02/06/2019 Non-covered Recipient Entity
Oviedo Medical Research
Bay1002670 Fibroids Efficacy US / EU No dispute reported 06/30/2026 629180275
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,708.00 02/06/2019 Non-covered Recipient Entity
Oviedo Medical Research
Bay1002670 Fibroids Efficacy US / EU No dispute reported 06/30/2026 629180403
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $517.00 02/06/2019 Non-covered Recipient Entity
Oviedo Medical Research
Bay1002670 Fibroids Efficacy US / EU No dispute reported 06/30/2026 629180529
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $2,490.00 02/06/2019 Non-covered Recipient Entity
Oviedo Medical Research
Bay1002670 Fibroids Efficacy US / EU No dispute reported 06/30/2026 629180779
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $704.00 02/06/2019 Non-covered Recipient Entity
Oviedo Medical Research
Bay1002670 Fibroids Efficacy US / EU No dispute reported 06/30/2026 629180901
Principal investigator 1 PFIZER INC. $48.00 02/01/2019 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH
A PHASE 3 RANDOMIZED DOUBLEBLIND ACTIVECONTROLLED MULTICENTER STUDY OF THE LONGTERM SAFETY AND EFFICACY OF SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR KNEE No dispute reported 06/30/2026 671638313
Principal investigator 1 Eli Lilly and Company $13,750.00 01/31/2019 Non-covered Recipient Entity
COMPASS RESEARCH EAST LLC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL ARM STUDY OF THE EFFICACY AND SAFETY OF INVESTIGATIONAL DULAGLUTIDE DOSES WHEN ADDED TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS No dispute reported 06/30/2026 654294563
Principal investigator 1 Novo Nordisk AS $750.00 01/29/2019 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH LLC
EX9536-4388 No dispute reported 06/30/2026 692457705
Principal investigator 1 Novo Nordisk AS $3,000.00 01/29/2019 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH LLC
EX9536-4388 No dispute reported 06/30/2026 692457707
Principal investigator 1 Novo Nordisk AS $1,000.00 01/29/2019 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH LLC
EX9536-4388 No dispute reported 06/30/2026 692457709
Principal investigator 1 Eisai Inc. $1,460.00 01/08/2019 Non-covered Recipient Entity
COMPASS RESEARCH, LLC
A Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel Group Study of the Safety and Efficacy of Lemborexant in Subjects With Insomnia Disorder No dispute reported 06/30/2026 702524971
Principal investigator 1 Eisai Inc. $1,595.00 01/08/2019 Non-covered Recipient Entity
COMPASS RESEARCH, LLC
A Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel Group Study of the Safety and Efficacy of Lemborexant in Subjects With Insomnia Disorder No dispute reported 06/30/2026 702524973
Principal investigator 1 Eisai Inc. $1,305.00 01/08/2019 Non-covered Recipient Entity
COMPASS RESEARCH, LLC
A Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel Group Study of the Safety and Efficacy of Lemborexant in Subjects With Insomnia Disorder No dispute reported 06/30/2026 702524975
Principal investigator 1 Eisai Inc. $1,460.00 01/08/2019 Non-covered Recipient Entity
COMPASS RESEARCH, LLC
A Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel Group Study of the Safety and Efficacy of Lemborexant in Subjects With Insomnia Disorder No dispute reported 06/30/2026 702524977
Principal investigator 1 Eisai Inc. $1,595.00 01/08/2019 Non-covered Recipient Entity
COMPASS RESEARCH, LLC
A Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel Group Study of the Safety and Efficacy of Lemborexant in Subjects With Insomnia Disorder No dispute reported 06/30/2026 702524979
Principal investigator 1 Eisai Inc. $1,305.00 01/08/2019 Non-covered Recipient Entity
COMPASS RESEARCH, LLC
A Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel Group Study of the Safety and Efficacy of Lemborexant in Subjects With Insomnia Disorder No dispute reported 06/30/2026 702524981
Principal investigator 1 Eisai Inc. $1,155.00 01/08/2019 Non-covered Recipient Entity
COMPASS RESEARCH, LLC
A Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel Group Study of the Safety and Efficacy of Lemborexant in Subjects With Insomnia Disorder No dispute reported 06/30/2026 702524983
Principal investigator 1 Eisai Inc. $1,305.00 01/08/2019 Non-covered Recipient Entity
COMPASS RESEARCH, LLC
A Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel Group Study of the Safety and Efficacy of Lemborexant in Subjects With Insomnia Disorder No dispute reported 06/30/2026 702524985
Principal investigator 1 Eisai Inc. $1,455.00 01/08/2019 Non-covered Recipient Entity
COMPASS RESEARCH, LLC
A Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel Group Study of the Safety and Efficacy of Lemborexant in Subjects With Insomnia Disorder No dispute reported 06/30/2026 702524987
Principal investigator 1 Novo Nordisk AS $117.78 01/03/2019 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706701195
Principal investigator 1 PFIZER INC. $48.00 01/01/2019 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH
A PHASE 3 RANDOMIZED DOUBLEBLIND ACTIVECONTROLLED MULTICENTER STUDY OF THE LONGTERM SAFETY AND EFFICACY OF SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR KNEE No dispute reported 06/30/2026 671638381